Eton Pharmaceuticals buys experimental drug

DEER PARK - Eton Pharmaceuticals said Wednesday it has acquired a hormone treatment candidate called ET-600 from Tulex Pharmaceuticals.

ET-600 is an product candidate under development for the treatment of an endocrinology condition that is estimated to impact less than 5,000 pediatric patients in the United States, the company said. Eton Pharmaceuticals specializes in the development and commercialization of treatments for rare diseases.

Financial terms of the acquisition were not disclosed.

"As a rare disease product that builds on our established presence in pediatric endocrinology, ET-600 is a perfect strategic fit for our portfolio," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "We have repeatedly heard from physicians about their need for this product to effectively and safely treat their pediatric patients, so we look forward to working to bring this potential new treatment option to the market."

Eton expects to submit a new drug application for the product to the U.S. Food and Drug Administration in the second quarter of 2024, which could allow for an approval and launch of the product in early 2025. If approved, ET-600 is expected to be a patent-protected, durable product that can generate significant long-term revenue and profit for the company, it said.